Evidence map›Paper›PMID 39664457›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2024

Single Apheresis Session on the 4th Day of Granulocyte Colony-Stimulating Factor Administration Seems Convenient to Collect Enough Peripheral Blood Stem Cells from Healthy Donors.

Orhan Kemal Yucel, Dilek Yapar, Ece Vural, Nurcan Alhan, Sertac Vurgun, Unal Atas, Mustafa Serkan Alemdar, Mustafa Karaca, Utku Iltar, Ozan Salim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Orhan Kemal YucelDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Dilek YaparDepartment of Public Health and Bioistatistics, Gazi University School of Medicine, Ankara, Turkey.
Ece VuralDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Nurcan AlhanDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Sertac VurgunDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Unal AtasDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Mustafa Serkan AlemdarDepartment of Medical Oncology, Antalya Research and Training Hospital, Antalya, Turkey.
Mustafa KaracaDepartment of Medical Oncology, Antalya Research and Training Hospital, Antalya, Turkey.
Utku IltarDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Ozan SalimDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.
Levent UndarDepartment of Hematology and Stem Cell Transplantation, Akdeniz University School of Medicine, Antalya, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To minimize adverse events of peripheral blood stem cell (PBSC) collection in healthy donors, it is reasonable to limit the total dose of granulocyte colony-stimulating factor (G-CSF) and/or the number of apheresis days without decreasing of PBSCs yield. Therefore, we have started to collect G-CSF induced PBSCs on day 4 instead of on day 5. So, we retrospectively aimed to investigate the results of this 4-day G-CSF administration. Study Design and Methods: Seventy-six healthy donors who performed on G-CSF induced PBSCs donation consecutively between January 2020 and July 2022 were included in this study. G-CSF (filgrastim) at 2 × 5 µg/kg/day subcutaneously was applied. Apheresis started on day 4. Results: Sixty-nine (90.8%) of 76 donors provided enough PBSCs on day 4 apheresis session. Younger age ( Conclusion: It seems that starting the apheresis on the 4th day of G-CSF administration is effective and to provide minimal G-CSF exposure in healthy donors.

Indexed as

Granulocyte colony-stimulating factorHealthy donorsPeripheral blood stem cellsVery good mobilizer

Identifiers

PMID39664457
PMCPMC11630901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.